A new module was introduced to FHT practices in July 2022 recommending SGLT2 inhibitor prescribing in patients with type 2 diabetes who also have CKD, CVD, or risk factors for CVD consistent with the Australian Evidence-Based Clinical Guidelines for Diabetes [5]. Here, SLC5A2 is linked to diabetes mellitus.